Small molecule inhibitors of BRAF in clinical trials.
Article Details
- CitationCopy to clipboard
Zambon A, Niculescu-Duvaz I, Niculescu-Duvaz D, Marais R, Springer CJ
Small molecule inhibitors of BRAF in clinical trials.
Bioorg Med Chem Lett. 2012 Jan 15;22(2):789-92. doi: 10.1016/j.bmcl.2011.11.060. Epub 2011 Dec 3.
- PubMed ID
- 22222036 [ View in PubMed]
- Abstract
Over the last few years, BRAF has emerged as a validated target in melanoma. This review summarises recent advances in the development of BRAF inhibitors, focussing on agents that have been assessed clinically.
DrugBank Data that Cites this Article
- Binding Properties
Drug Target Property Measurement pH Temperature (°C) PLX-4720 Serine/threonine-protein kinase B-raf IC 50 (nM) 13 N/A N/A Details Regorafenib Serine/threonine-protein kinase B-raf IC 50 (nM) 28 N/A N/A Details